ArticleJournal of nanobiotechnology2020
Neutrophils mediated multistage nanoparticle delivery for prompting tumor photothermal therapy.
Article in Journal of nanobiotechnology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Review
- Harnessing myeloid cells in cancer.Molecular cancer · 2025Review
- From micro to macro, nanotechnology demystifies acute pancreatitis: a new generation of treatment options emerges.Journal of nanobiotechnology · 2025Review
- Targeting Cancer: Microenvironment and Immunotherapy Innovations.International journal of molecular sciences · 2024Review
- Convergence of nanomedicine and neutrophils for drug delivery.Bioactive materials · 2024Article
- Theoretical basis, state and challenges of living cell-based drug delivery systems.Theranostics · 2024Review
- mRNA as a medicine in nephrology: the future is now.Clinical kidney journal · 2023Review
- Messenger RNA-Based Therapeutics and Vaccines: What's beyond COVID-19?ACS pharmacology & translational science · 2023Review
- Regulating the microenvironment with nanomaterials: Potential strategies to ameliorate COVID-19.Acta pharmaceutica Sinica. B · 2023Review
- Unlocking the promise of mRNA therapeutics.Nature biotechnology · 2022Review
- Next-generation engineered nanogold for multimodal cancer therapy and imaging: a clinical perspectives.Journal of nanobiotechnology · 2022Review
- Design of a Platelet-Mediated Delivery System for Drug-Incorporated Nanospheres to Enhance Anti-Tumor Therapeutic Effect.Pharmaceutics · 2021Article
- Identification of an Aptamer With Binding Specificity to Tumor-Homing Myeloid-Derived Suppressor Cells.Frontiers in pharmacology · 2021Article
- The Advances of Neutrophil-Derived Effective Drug Delivery Systems: A Key Review of Managing Tumors and Inflammation.International journal of nanomedicine · 2021Review
Corrections and comments
- Erratum issued
Authors and funding
8 authors.
Funding
Abstract
backgroundNeutrophil-based drug delivery system possesses excellent advantages in targeting at tumour because neutrophils are easily recruited by chemotactic factor in tumor microenvironment. Herein, we developed a novel tactic of multistage neutrophils-based nanoparticle delivery system for promoting photothermal therapy (PTT) of lung cancer.
resultsAu nanorod (AuNR) was successfully modified with bovine serum albumin (AuNRB) and further conjugated with RGD (AuNRBR), followed by neutrophil internalisation to obtain neutrophils-based delivery system (AuNRBR/N). The engineered neutrophils efficiently migrated across the epithelial cells due to inflammatory signal. They exhibited better toxicity against Lewis cells with laser irradiation in vitro. Moreover, AuNRBR/N showed significantly more targetability to tumour tissue compared with cell carrier-free AuNRBR, as demonstrated in Lewis tumour-bearing mice. The enhanced tumour homing efficiency of AuNRBR/N together with subsequently released AuNRBR from the neutrophils was favourable for further deep tissue diffusion and contributed to the inhibition of the tumour growth in PTT and improved survival rate (over 120 days).
conclusionsOverall results illustrated that the design of cell-based nanoparticle delivery system for PTT of cancer is promising.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.